Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 5.1% – Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) rose 5.1% during mid-day trading on Friday . The company traded as high as $21.44 and last traded at $21.31. Approximately 19,674 shares traded hands during trading, a decline of 90% from the average daily volume of 205,134 shares. The stock had previously closed at $20.27.

Analysts Set New Price Targets

DNTH has been the subject of several analyst reports. Oppenheimer boosted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Wedbush decreased their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Raymond James boosted their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Trading Up 5.2 %

The stock’s 50 day moving average price is $27.10 and its 200 day moving average price is $26.59. The firm has a market cap of $631.01 million, a PE ratio of -8.56 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Barclays PLC lifted its stake in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $556,000. Wellington Management Group LLP purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $1,473,000. State Street Corp grew its position in shares of Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after acquiring an additional 263,500 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.